{
  "id": 6443856,
  "title": "FDA should follow EMA's lead on drug rejection disclosures, researchers say",
  "url": "https://urgent.news/2026/09/09/fda-should-follow-emas-lead-on-drug-rejection-disclosures-researchers",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-09T16:51:11.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/fda-should-follow-emas-lead-on-drug-rejection-disclosures-researchers-say/"
  },
  "original_language": "en",
  "account": null,
  "summary": "The FDA's major shift in September 2025 to begin publishing drug rejection letters is still an evolving process. But moving forward, the US agency should improve its releases by learning from the European Medicines Agency's ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}